SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2432Does 100% funding of the REGN3500 (anti-IL33 abs) by Sanofi EXPLAIN slow progresMiljenko Zuanic-6/4/2018
2431biopharmadive.com Maybe, there is opportunity for Dupi (or/and anti-IL33) in CMiljenko Zuanic-5/30/2018
2430What is interesting about Neil Stahl (VP, R&D) is that after 30 years at REGMiljenko Zuanic-5/28/2018
2429No, S. Nell converted stock-options that would expired on 12-2020, so at least 2Miljenko Zuanic-5/28/2018
2428Aren't these just scheduled sells from their end?Felix B-5/28/2018
2427Now, not only idiots-Directors sell and profit from generous options, but also oMiljenko Zuanic-5/26/2018
2426J&J (Genmab) disconinued development of the anti-CD38 (Darzalex) -IO combinaMiljenko Zuanic15/26/2018
2425great questionFelix B-5/24/2018
2424Why is REGN presenting at Barclays, when they have SELL rating on company? Who iMiljenko Zuanic-5/24/2018
2423What is probability of that route to happen? Or, is that just Gov. "leveragMiljenko Zuanic-5/23/2018
2422If Medicare Part B gets merged into Medicare Part D (a proposal being discussed DewDiligence_on_SI-5/23/2018
2421Again, we have negative vibrations from CMS. Just as note, Eylea was the most bMiljenko Zuanic-5/22/2018
2420Similar in ORR.Miljenko Zuanic-5/17/2018
2419How does that compare to MRK and BMS?Felix B-5/16/2018
2418Cemiplimab abstract (PR) at ASCO: newsroom.regeneron.com ~30% response (6/21) rMiljenko Zuanic-5/16/2018
2417Adolescents AD cleared: finance.yahoo.comMiljenko Zuanic-5/16/2018
2416Message 31611570Julius Wong-5/11/2018
2415Azar is really enjoying this circus!Miljenko Zuanic-5/11/2018
2414US Government and Rx cost control = "CIRCUS"!Miljenko Zuanic15/11/2018
2413Latest from IR: files.shareholder.com new on 2810 (slide 21), 2L NSCLC, mono anMiljenko Zuanic-5/11/2018
2412Interesting presentation from P1 CSCC trial: files.shareholder.com MB>60/MbMiljenko Zuanic-5/9/2018
2411RE:2810 at ASCO Some optimism can be expected from 2L BCC trial (options for &qMiljenko Zuanic-5/8/2018
2410KEYNOTE-598 clinicaltrials.gov KEYNOTE-006 clinicaltrials.gov Not the same, notMiljenko Zuanic15/6/2018
2409...do not understand what they want to achieve by combining 2810 with Ipi, when DewDiligence_on_SI-5/6/2018
2408Also unsure if their approach with Ipi...Felix B-5/6/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News